TREH and obesity due to melanocortin 4 receptor deficiency: This evidence implies that systemic Treh is not a clinically appropriate target for treating obesity and related complications, but this does not exclude the possibility of potential metabolic benefits related to tissue-specific suppression of Treh, which should be further studied.